Characterization of Neuronal Tau Protein as a Target of Extracellular Signal-regulated Kinase by Qi, H et al.
Characterization of Neuronal Tau Protein as a Target of
Extracellular Signal-regulated Kinase*
Received for publication,October 28, 2015, and in revised form, January 20, 2016 Published, JBC Papers in Press, February 8, 2016, DOI 10.1074/jbc.M115.700914
Haoling Qi‡, Sudhakaran Prabakaran§, François-Xavier Cantrelle‡, Béatrice Chambraud¶, Jeremy Gunawardena§,
X Guy Lippens‡, and Isabelle Landrieu‡1
From ‡Lille University, CNRS UMR8576, F-59000 Lille, France, §Department of Systems Biology, HarvardMedical School, Boston,
Massachusetts 02115, and ¶INSERMUMR1195 Paris SUD University, Le Kremlin Bicêtre 94276, France
Tau neuronal protein has a central role in neurodegeneration
and is implicated in Alzheimer disease development. Abnormal
phosphorylation of Tau impairs its interaction with other pro-
teins and is associated with its dysregulation in pathological
conditions.Molecularmechanisms leading to hyperphosphory-
lation of Tau in pathological conditions are unknown. Here, we
characterize phosphorylation of Tau by extracellular-regulated
kinase (ERK2), a mitogen-activated kinase (MAPK) that re-
sponds to extracellular signals. Analysis of in vitro phosphory-
lated Tau by activated recombinant ERK2 with nuclear mag-
netic resonance spectroscopy (NMR) reveals phosphorylation of
15 Ser/Thr sites. In vitro phosphorylation of Tau using rat brain
extract and subsequent NMR analysis identifies the same sites.
Phosphorylation with rat brain extract is known to transform
Tau into an Alzheimer disease-like state. Our results indicate
that phosphorylation of Tau by ERK2 alone is sufficient to pro-
duce the same characteristics.We further investigate themech-
anism of ERK2 phosphorylation of Tau. Kinases are known to
recognize their protein substrates not only by their specificity
for a targeted Ser or Thr phosphorylation site but also by bind-
ing to linear-peptide motifs called docking sites. We identify
two main ERK2 docking sites in Tau sequence using NMR. Our
results suggest that ERK2 dysregulation in Alzheimer disease
could lead to abnormal phosphorylation of Tau resulting in the
pathology of the disease.
Tau is an intrinsically disordered protein whose primary
sequence is divided into several functional domains: an N-ter-
minal region, a proline-rich domain (PRD),2 a microtubule
binding domain (MTBD) constituted of partially repeated
sequences R1 to R4, and a C-terminal region (see Fig. 1A). Both
PRD andMTBDare involved inmicrotubule stabilizing activity
of Tau (1, 2).
Phosphorylation of Tau is an essential process to regulate its
physiological function(s); however, abnormal phosphorylation
of Tau has been linked to neuronal dysfunction (3–5). In
Alzheimer disease (AD) Tau is hyperphosphorylated and
aggregated (6). The longest Tau protein isoform (441 residues)
has 80 threonine (Thr) or serine (Ser) residues. These residues
are exposed as Tau is an intrinsically disordered protein subject
to modification by numerous kinases (7). Mass spectrometry
(MS) analyses have identified45 phosphorylated sites on Tau
aggregates extracted from AD patients with a typical paired
helical filament (PHF)morphology (8, 9) compared with 15–30
phosphorylation sites in soluble Tau extracted from mice (10)
or normal human brain (11). Monoclonal antibodies such as
AT8 (recognizing Ser(P)-202/Thr(P)-205; Ref. 12) or PHF1
(Ser(P)-396/Ser(P)-404; Ref. 13) are often used to detect abnor-
mal phosphorylation of Tau (5). Proline-directed kinases with a
(S/T)P phosphorylation consensusmotif, such as cyclin-depen-
dent kinase 5 (CDK5; Refs. 14 and 15) with its activator protein
p25, glycogen synthase kinase (GSK3; Ref. 16), stress-acti-
vated protein kinases (JNK; Ref. 17), and p38 (18) and extracel-
lular-signal-regulated kinase (ERK1/2; Ref. 19), are considered
as potential therapeutic targets to prevent Tau hyperphosphor-
ylation (20). A clear understanding of themechanism of abnor-
mal phosphorylation of Tau leading to neuronal dysregulation
is still lacking. Characterization of the kinases involved in the
phosphorylationofTauandtherelatedspecificpatternsofphos-
phorylation are, therefore, of interest to develop new strategies
to counteract the pathological processes.
ERK2 belongs to the mitogen-activated protein kinase
(MAPKs) family and is activated by dual phosphorylation on a
Thr-Xaa-Tyr sequence in its activation loop by MAP kinase
kinases (MKK) (21–23). Human ERK2 is phosphorylated on
Thr-183 and Tyr-185 byMEK kinase. MAP kinases have a clas-
sic kinase structure with an N-terminal lobe folded as a  sheet
associated to a larger C-terminal domain constituted of -heli-
ces (24). The activation loop is located at the hinge between
these domains and shows a large conformational change upon
phosphorylation (25). Mechanisms regulating specificity and
efficiency of kinases are not fully understood but involve the
binding of kinase docking grooves to binding motifs on their
substrates, made up of a linear peptide (26, 27). Interaction
regions distinct from the catalytic pocket were found to be
involved in the recognition of both ERK1/2 upstream regula-
tors and downstream substrates (28). The ERK docking site is
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targeted by proteins that contain a linear motif called the D-re-
cruitment site (DRS or D-site), defined by a loose consensus of
10 amino acid residues1–3 X3–7X (,, and X refer to
positively charged, hydrophobic, or any intervening residues,
respectively, and subscripts refer to the number of residues
(30)). Interactions of the conserved D-recruitment site motifs
with theMAP kinase docking site has been characterized at the
atomic level in complexes of ERK2with peptide fragments from
several protein partners (30–33). In addition, another docking
motif was identified, called F-recruitment site (FRS or F-site)
that recognizes a Phe-Xaa-Phe motif (34).
ERK1/2 activation in AD brain is well documented (35–37).
Results from previous studies indicate that ERK1/2 is able to
transform Tau into an AD-like state, but this is mainly docu-
mented by the detection of the epitope recognized by the AT8
antibody (19). To better define the phosphorylation sites
involved in the transformation of Tau as present in AD (19), we
usedNMR spectroscopy.We observed that 14 out of the 17 S/T
sites, which are followed by proline ((S/T)P sites) and likely to
be recognized by proline-directed ERK1/2, are phosphorylated
by activated recombinant ERK2 in vitro. Another well known in
vitro model of Tau hyperphosphorylation is obtained by incu-
bation of Tau with rat brain extracts along with phosphatase
inhibitor okadaic acid (38). We compared the phosphorylation
pattern of Tau obtained using rat brain extract with that
obtained using the in vitro activated recombinant ERK2. A sim-
ilar pattern of Tau phosphorylation was indeed observed,
which strongly suggests that ERK2 is sufficient for hyperphos-
phorylation of Tau.We then studied theTau-ERK2 interaction.
We mapped the interaction sites of ERK2 along the Tau
sequence and identified two docking sites in the MTBD, which
is distal to the PRD containingmost of the ERK phosphorylated
sites of Tau.We, therefore, conclude that Tau and ERK2 form a
dynamic complex. Our study indicates that Tau could be the
first example of an ERK2 substrate with multiple docking sites.
These conclusions expand our view on the potential role of
ERK2 in the neurodegeneration pathway in AD involving Tau
and shed light on the molecular mechanisms leading to patho-
logical Tau formation.
Experimental Procedures
Molecular Cloning—cDNA encoding peptides Tau-(220–
240) and Tau-(271–294) were amplified from Tau full-length
cDNA by PCR. The cDNA were cloned by a ligation-indepen-
dent protocol into vector pETNKI-HisSUMO3-LIC (39).
Preparation of Recombinant Proteins—The longest isoform
of Tau (441 amino acid residues) and the Tau fragments Tau-
(165–245) and Tau-(244–372) (K18) were expressed and puri-
fied as recombinant proteins from Escherichia coli Bl21(DE3)
(New England BioLabs) using pET15b plasmid (Invitrogen)
under the control of T7lac promoter. Tau fragments Tau-
(220–240) and Tau-(271–294) were expressed as N-terminal
fusion with the SUMO protein presenting a N-terminal His tag
from a modified pET vector (39).
Bacteriawere grown in LBmediumat 37 °C and recombinant
protein production induced with 0.4 mM isopropyl-1-thio--D-
galactopyranoside. Isotope labeling was performed using a
modified M9 medium containing in addition to the M9 salts,
minimum Eagle’s medium vitamin mix 1 (Sigma), 1 g of
[15N]NH4Cl, 4 g of glucose or 2 g of [13C]glucose and 200mg of
complete medium powder (Celtone Complete Medium, Cam-
bridge Isotope Laboratories) per liter of bacterial culture.
Briefly, Tau protein, Tau-(165–245) and Tau-(244–372) frag-
ments were purified by first heating the bacterial extract 15min
at 75 °C. Purification consisted of cation exchange chromatog-
raphy with a sodium phosphate buffer at pH 6.5 (Hitrap SP-
Sepharose FF, 5ml; GEHealthcare) for Tau andTau-(165–245)
and nickel-chelating chromatography for Tau-(244–372)
(Hitrap nickel-Sepharose FF, 5 ml; GE Healthcare). Full-length
Tau protein and Tau fragments were then buffer-exchanged
against ammonium bicarbonate (Hiload 16/60 desalting col-
umn,GEHealthcare) for lyophilization.His-SUMOTau-(220–
240) and His-SUMO Tau-(271–294) were purified by affinity
chromatography on nickel-nitrilotriacetic acid resin following
the manufacturer’s protocols. The fusion proteins were buffer-
exchanged using a PD-10 column (G25 resin, cutoff of 7 kDa;
GE Healthcare) against NMR buffer.
Recombinant His6-tagged p42 MAP kinase (ERK2) from
Xenopus laevis was prepared by growing bacteria transformed
with a ERK recombinant T7 expression plasmid in LB medium
until induction by 1 mM isopropyl 1-thio--D-galactopyrano-
side of the protein production for a period of 4 h at 37 °C. His-
ERK2 was purified using nickel-nitrilotriacetic acid-based
affinity chromatography following the manufacturer’s proto-
cols. After analysis on SDS-PAGE, the pooled fractions were
buffer-exchanged using a PD-10 column (GE Healthcare)
against conservation buffer 50 mM Tris-HCl, 150 mMNaCl, 0.1
mM EGTA, 50% glycerol, pH 7.5, and kept frozen at 80 °C.
His6-tagged D321N/D324N ERK2 was prepared in the same
manner. Activated-ERK2 was prepared as previously described
by in vitro incubation with activated MEK (40).
To label Tau with CF3 attached on its native Cys residues
(Cys-291 and Cys-322), 100 M [15N]Tau or [15N]Tau-(244–
372) in 50 mM ammonium bicarbonate were first thoroughly
reduced by incubation for 2 h at 22 °Cwith 1mMTris (hydroxy-
methyl) phosphine reducing agent. The protein samples were
next incubated with 2 mM 2-iodo-N-trifluoroethyl acetamide
(EnamineStore) in dimethyl sulfoxide at 22 °C for 3 h. The
excess of 2-iodo-N-trifluoroethyl acetamide was removed by
desalting. The CF3-[15N]Tau samples were lyophilized.
In Vitro Phosphorylation of Tau Protein—15N-Labeled
recombinant Tau was used as substrate to assay the activity of
activated ERK2. 100 M [15N]Tau or [15N]Tau-(165–245) was
incubated with 1 M ERK2 enzyme at 37 °C for 3 h in 200 l of
phosphorylation buffer 50mMHepes, pH 8.0, 50mMNaCl, 12.5
mMMgCl2, 2.5mMATP, 2mMDTT, 1mMEDTA, 2mMEGTA,
and protease inhibitor mixture (Roche Applied Science, Com-
plete Inhibitors without EDTA). To identify the phosphoryla-
tion sites by NMR spectroscopy 13C,15N-double-labeled Tau
was incubated in the same conditions overnight with the acti-
vated recombinant ERK2. Enzymatic incubation was termi-
nated by heating the reaction mixture for 15 min at 75 °C fol-
lowed by centrifugation. The phosphorylation mixture was
buffer-exchanged using desalting centrifugal devices (0.5-ml-
bed G25 resin, cutoff of 7 kDa, Thermo Scientific Zeba Desalt-
ing Columns) against NMR buffer (50 mM deuterated Tris, pH
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6.65, 25 mM NaCl, 2.5 mM EDTA, 1 mM DTT and 10% D2O).
Phosphorylation of the Tau-(165–245) by ERK2 followed the
same protocol. For the time course of phosphorylation, 100M
[15N]Tau was incubated for 15, 30, 60, 120, and 180 min with 1
M activated-ERK2 as described above. The reaction was
stopped by heating the sample at 75 °C for 15 min. The exper-
iment was repeated three times.
The rat brain extract was prepared by homogenizing a brain
(2 g) in 5ml of homogenizing buffer (10mMTrisCl, pH 7.4, 5
mM EGTA, 2 mM DTT, 1 M okadaic acid (Sigma) supple-
mented with 20 g/ml leupeptin and 40 mM Pefabloc (38).
Ultracentrifugation was next performed at 100,000 g for 1 h
at 4 °C. The supernatant was directly used for its kinase activity.
Total protein concentrationwas estimated to be 7mg/ml by the
Bradford colorimetric assay. The [15N]Tau protein (1–1.5 mg)
was dissolved at 10 M in 2.5 ml of phosphorylation buffer (2
mM ATP, 40 mM HepesKOH, pH 7.3, 2 mM MgCl2, 5 mM
EGTA, 2 mM DTT complemented with a protease inhibitor
mixture (Roche Applied Science) and 1 M okadaic acid
(Sigma). The phosphorylation reaction was performed at 37 °C
for 24 h with 500 l of brain extract. Enzymatic incubation was
terminated by heating the reaction mixture for 15 min at 75 °C
followed by centrifugation. Phosphorylation mixture was buf-
fer-exchanged against 50 mM ammonium bicarbonate before
lyophilization. Phosphorylation of the Tau-(165–245) by rat
brain extract kinase activity followed the same protocol. The
samples were prepared by solubilizing the lyophilized powder
into NMR buffer. Each set of experiment was independently
repeated two or three times.
NMR Spectroscopy—Analysis of the phospho-Tau samples
by NMR spectroscopy was performed at 293 K or 298 K on
Bruker 600-MHz and 900-MHz spectrometers equipped with a
triple resonance cryogenic probehead (Bruker, Karlsruhe, Ger-
many). Trimethylsilyl propionate was used as the reference (0
ppm). 100 M [15N]Tau in a volume of 200 l in 3-mm tubes
was sufficient to obtain the two-dimensional 1H,15N heteronu-
clear single quantumcorrelation (HSQC) spectrawith 32 scans.
HSQC two-dimensional experiments to map the interaction
between Tau protein and recombinant ERK2 were recorded at
293 K on a 900-MHz spectrometer with 64 scans per increment
as a complex matrix of 2048 416 complex points for 14 25
ppm spectral widths in the proton and nitrogen dimensions,
respectively. Three-dimensional HNCACB spectra were
recorded for 13C,15N-phospho-Tau obtained both with rat
brain extract and recombinant ERK2 with a standard Bruker
pulse sequence. A three-dimensional HNcaNNH spectrum
(41) was additionally used in the assignment. Three-dimen-
sional HNCACB experiments were acquired to confirm the
assignment of the Tau residues in 13C,15N-His-SUMO Tau-
(220–240) and 13C,15N-His-SUMO Tau-(271–294). For Fluor
NMR experiments, the lyophilized CF3-[15N]Tau and CF3-
[15N]Tau-(244–372) were suspended in phosphate NMR
buffer consisting of phosphate buffered saline, pH 7.4, 2.5 mM
EDTA, and 2mMDTT. 50MCF3-Tau or CF3-Tau-(244–372)
in 200 l of phosphate NMR buffer were titrated with increas-
ing concentration of His-ERK2 (25, 50, 100, 125, 162, and 220
M). The one-dimensional 19F spectra were recorded at 293 K
with 1024 scans on a Bruker 600MHz Avance NMR spectrom-
eter equipped with a 5-mm CPQCI 19F/1H-13C/15N cryogenic
probehead (Bruker). The chemical shifts in one-dimensional
19F spectra were referenced by using the fluor resonance of
external Trifluoroacetic acid at76.55 ppm.
NMR Data Processing—Spectra were processed with Bruker
TopSpin 3.1 software. Data analysis, peak picking, and calcula-
tion of peak volumes were done with Sparky 3.114 software
(T. D. Goddard and D. G. Kneller, SPARKY 3, University of
California, San Francisco). Assignment of resonances of
Thr(P)- and Ser(P)-phosphorylated residues is based on the
typical C and C chemical shifts of these residues (42). Ser(P)
and Thr(P) resonances were assigned to a specific residues in
phospho-Tau primary sequence using as additional informa-
tion the 15N C and C chemical shifts of their N-terminal
residues (43–45) (Table 1). Resonance integration was per-
formed in two-dimensional spectra by summing all the inten-
sities over a box enclosing the peak of interest. To account for
variations between spectra, integration volumes were normal-
ized to the integration value of the resonance of Glu-62 residue,
which is isolated in the spectrum and not influence by phos-
phorylation(s). To estimate the level of phosphorylation at each
site, we first estimated the level of phosphorylation on Thr-153
residue using the resonances of Ala-152. Ala-152 has two dis-
tinct resonances in the two-dimensional 1H,15N spectrum
depending on the phosphorylation status of Thr-153 residue.
The ratio of the integration volumes of these Ala-152 reso-
nances gives an estimation of the phosphorylation degree of
Thr-153. We next used this value to correlate integration vol-
umes of resonances with phosphorylation level of the corre-
sponding phospho-residue.
In Vitro Aggregation Assay—Tau aggregation assays were
performed at 0.25mg/ml (5M) Tau (incubated overnight with
activated recombinantERK2kinase in absenceofATP)orphos-
phorylated Tau in MES buffer consisting of 100 mM MES, pH
6.9, 2 mM EGTA, 1 mM MgCl2, and 0.3 mM freshly prepared
DTT. The samples were incubated at 35 °C with shaking at 300
rpm. After 2 h of incubation, the insoluble fraction was col-
lected by centrifugation at 16,500  g, and the pellet was sus-
pended in 50 l.
10-l samples were applied on 400-mesh hexagonal Form-
var-coated copper grids for 45 s. The sample-loaded grids were
washed twice by ion-free water and drained. The grids were
next negatively stained with 2% urinyl acetate solution for 60 s.
The observation was performed by transmission electron
microscopy (Hitachi H7500 at 80 kV and JEOL JEM-2100 at
200 kV.
Interaction of ERK2 with Tau, Tau Fragments, and Tau
Peptides—ERK2 buffer exchange after storage was done using
desalting centrifugal devices (1.5-ml-bed of G25 resin, cutoff of
7 kDa; Thermo Scientific Zeba Desalting Columns). ERK2 pro-
tein in Tris NMR buffer was then concentrated to a volume of
200 l using a centrifugal concentrator (0.5 ml, 30 K mem-
brane, Amicon Ultra) up to 250 M. The concentrated enzyme
solution was directly used to suspend lyophilized [15N]Tau,
[15N]Tau-(244–372) (K18) and [15N]Tau-(165–245) to a final
concentration of 50–80 M labeled samples. For the interac-
tion with Tau peptides, 15N-His-Sumo Tau-(220–240) peptide
or 15N-His-SUMOTau-(271–294) peptide were directly mixed
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with ERK2 in the NMR buffer to a final concentration of 50 M
concentrations of labeled peptides. The ERK2 samples were
prepared freshly before the NMR experiments due to the tend-
ency of the ERK2 protein to precipitate in the NMR buffer
conditions.
Results
Identification of TauAmino Acids Phosphorylated in Vitro by
ERK2—We used NMR spectroscopy to identify phosphoryla-
tion sites of Tau modified in vitro by activated ERK2. On incu-
bation with MEK-activated recombinant ERK2 (double-phos-
phorylated onThr-183/Tyr-185), several additional resonances
were observed in the 1H,15N two-dimensional spectrum for the
resulting phospho-Tau compared with the spectrum of the
unphosphorylated Tau (compare Fig. 1, B and C). These reso-
nances are typical for the HN amide resonances of Ser(P) and
Thr(P) residues (42,44), indicating thatTau is indeedphosphor-
ylated at many sites by ERK2. Phosphorylation sites were iden-
tified using three-dimensional triple resonance NMR spectros-
copy on a 13C,15N-labeled Tau sample phosphorylated in vitro
by activated ERK2. Of the 17 (S/T)P sites, 14 sites along the Tau
sequence were found to be phosphorylated by ERK2 (Fig. 2, A
and B; Table 1). ERK2 phosphorylated Thr-50, Thr-153, Thr-
175, Thr-181, Thr-205, Thr-231, Ser-235, Ser-404, and Ser-422
with a stoichiometry of 50%; estimation was based on peak
integration (45) (Fig. 2B, Table 1). In addition, a minor phos-
phorylation was observed for Ser-191, which is not a Pro-di-
rected site (Fig. 2, Table 1). Phosphorylation by ERK2 of a Tau-
(165–245) fragment encompassing the PRD of Tau allowed
confirmation of the identification of the phosphorylation sites
located in this domain (Fig. 2C). A comparison with previous
assignments of the NMR amide cross-peaks corresponding
to Tau proline-directed phosphorylation sites, generated by
cyclin-dependent kinase 2/CycA3 or glycogen synthase kinase
3 (GSK3) (46, 47), further confirmed identification of the ERK2
phosphorylation sites located in the PRD and C-terminal
region. Kinetic experiments were next performed to define the
order of the multiple phosphorylations of Tau by recombinant
ERK2. SDS-PAGEanalysis ofTauduring a time-course of phos-
phorylation by activated ERK2 showed a gradual decreased
mobility associated with a global increase of Tau phosphoryla-
tion level (Fig. 3A). A series of two-dimensional spectra was
then acquired corresponding to various incubation times to get
insight at site-specific time-dependent modification of Tau by
ERK2. The level of modification at each identified phosphory-
lation site was estimated by the integral of the corresponding
resonance. The fastest observed phosphorylation was found for
Ser-235, Ser-404, and Ser-422 followed by Thr-50, Thr-181,
and Thr-205 (Fig. 3, B–D). The time-dependent phosphoryla-
tion increase for these residues can be fitted with an exponen-
tial function, with rate constants ranging from 10 to 85 min.
Slower modification was observed for residues Ser-46, Thr-69,
Thr-153, Thr-175, Ser-191, Ser-199, Thr-231, and Ser-396, which
showed a linear trend of phosphorylation increase during the 3-h
time course of Tau incubation with activated-ERK2.
Comparison of ERK2-phosphorylated Tau with a Hyperphos-
phorylation Model of Tau—Phosphorylation of S/T residues
corresponding to 12–15 sites has similarly been reported after
incubation of Tau with rat brain extract (12, 38, 48). The site-
specific, precise pattern of the hyperphosphorylation of Tau by
rat brain extract was, however, never investigated. We, there-
fore, used NMR spectroscopy to establish the map of Tau
amino acid residues phosphorylated by kinases in rat brain
extract and compared with those phosphorylated by ERK2. Rat
brain extracts were used to in vitro phosphorylate recombinant
15N-labeled Tau. The corresponding 1H,15N two-dimensional
spectrum of the phosphorylated Tau showed additional reso-
nances in the region for Thr(P) and Ser(P) residues compared
with the spectrum of the unphosphorylated Tau (Fig. 1, com-
FIGURE 1.Phosphorylationof Tau.A, schemeof the domain organization of Tau protein. Limits of the domains are indicated by the amino acid number in the
sequence. B–D, 1H,15N HSQC two-dimensional spectra of Tau (B), Tau phosphorylated byMEK-activated recombinant ERK2 (C), and Tau phosphorylated by rat
brain extract kinase activity (D). The region of the spectrum containing resonances corresponding to phosphorylated S/T residues is boxed in C andD spectra.
Detailed annotation of the resonances corresponding to phosphorylated residues is provided in Fig. 2B.
Phosphorylation of Tau by ERK2
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pare panels D and B). Comparison of two-dimensional spectra
of Tau phosphorylated by either activated ERK2 or rat brain
extracts showed that many resonances assigned to the ERK2
phosphorylated sites have a match in the brain extract phos-
phorylated Tau (Fig. 2, A and B). To confirm that the similarity
in the phospho-Tau spectra reflects a shared phosphorylation
pattern, phosphorylation sites were identified using three-di-
mensional triple resonance NMR spectroscopy on a 13C,15N-
labeled Tau phosphorylated in vitro by rat brain extract. The
major modified sites of Tau correspond to Ser(P)-46, Thr(P)-
50, Thr(P)-153, Thr(P)-175, Thr(P)-181, Ser(P)-202, Thr(P)-
205, Ser(P)-208, Thr(P)-231, Ser(P)-262, Ser(P)-356, Ser(P)-
396, Ser(P)-404, and Ser(P)-422 (Fig. 2). This analysis
confirmed that the overlapping resonances in the two-dimen-
sional spectra indeed correspond to the same phosphorylated
residues. The level of phosphorylation for these residues is also
similar between Tau phosphorylated by the rat brain extract or
the activated ERK2 (Fig. 2B). A few additional Tau phosphory-
lation sites are also identified exclusively from the incubation
with the rat brain extract including Ser(P)-208, Ser(P)-262, and
Ser(P)-356 that are not proline-directed sites (Fig. 2B). Phos-
phorylation with the brain extract of Tau-(165–245) fragment,
corresponding to the PRD, resulted in detection in the corre-
sponding two-dimensional 1H,15N HSQC of resonances corre-
sponding to phosphorylated residues. These phosphorylated
sites matched those found in the PRD embedded in the full-
length phosphorylated Tau protein (Fig. 2D), confirming the
assignment. The data showed that the pattern of phosphoryla-
FIGURE2.ComparisonofTauphosphorylationbyactivated recombinantERK2and ratbrainextracts.A, overlaiddetails of 1H,15NHSQC two-dimensional
spectra of phosphorylated Tau by activated ERK2 (in red) or by rat brain extract (in black). The enlarged region corresponds to the boxed region in Fig. 1. C and
D, resonances corresponding to assigned phosphorylated Tau residues are annotated. B, level of phosphorylation for each Ser(P)-/Thr(P)-Tau residue pre-
sented as black bars for Tau phosphorylated by the rat brain extract and red bars by activated ERK2. Each experiment was repeated twice. S.D. around average
value is shown by error bars. The level of phosphorylation is estimated based on the integrals of resonance peaks as described under “Experimental Proce-
dures.” C and D, 1H,15N HSQC two-dimensional spectrum of Tau-(165–245) modified by incubation at 37 °C for 3 h with activated recombinant ERK2 (C) or
overnight with rat brain extract (D). The annotated resonances were assigned to phosphorylation sites by comparisonwith the 1H,15N HSQC two-dimensional
spectrum of Tau protein phosphorylated by activated recombinant ERK2 or rat brain extract in the same conditions.
TABLE 1
Sequence specific assignment of resonances corresponding to phos-
phorylated residues in ERK phospho-Tau
1H, 15N, CA, and CB columns correspond to the chemical shifts (in ppm) of atoms
from the assigned phospho-residues indicated in the first column. The amino acid
type at the direct N terminus of each phospho-residue is displayed in column i-1
residue type and the chemical shifts of the correspondingCA andCB atoms inCA-1
and CB-1 columns.
Phosphorylated
amino acids 15N 1H CA CB CA-1 CB-1
i-1 residue
type
ppm ppm ppm ppm ppm ppm
Ser(P)-46 120.4 8.80 56.1 64.9 57.4 30.9 Glu
Thr(P)-50 123.5 9.30 61.1 72.2 55.6 30.2 Gln
Thr(P)-69 122.5 9.13 60.7 72.2 58.4 64.1 Ser
Thr(P)-153 121.8 9.35 61.1 72.2 52.4 19.4 Ala
Thr(P)-175 125.1 9.59 61.5 72.4 55.7 33.3 Lys
Thr(P)-181 124.5 9.49 61.3 72.4 55.9 33.3 Lys
Ser(P)-191 119.0 9.04 58.3 65.6 56.0 33.3 Lys
Ser(P)-199 120.6 8.71 56.0 65.0 57.7 64.3 Ser
Ser(P)-202 117.9 8.54 55.7 65.3 45.0 - Gly
Thr(P)-205 117.1 8.62 60.4 71.8 45.0 - Gly
Thr(P)-231 123.0 9.33 60.9 72.2 55.8 31.0 Arg
Ser(P)-235 120.0 8.85 55.8 65.2 56.5 33.3 Lys
Ser(P)-396 121.8 8.86 56.5 64.5 56.5 34.1 Lys
Ser(P)-404 120.4 8.66 55.9 70.0 61.7 70.0 Thr
Ser(P)-422 118.2 8.65 56.2 65.0 54.3 41.6 Asp
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tion obtained solely by ERK2 activity is similar to the one of the
hyperphosphorylated Tau obtained by incubation with rat
brain extract.
Aggregation Propensity of Tau Phosphorylated by Rat Brain
Extracts or Activated ERK2—Tau phosphorylated by rat brain
extract was shown to be able to self-assemble without the addi-
tion of an exogenous compound such as heparin (48). Given the
similarity in the phosphorylation pattern of Tau phosphorylat-
ed by the rat brain extract or activated ERK2, we next evaluated
the aggregation propensity of the later. Phosphorylated Tau
samples by either rat brain extract or ERK2 were incubated at
35 °C, and the insoluble fraction of the sample was observed by
electron microscopy. In both cases fibers of phospho-Tau were
observed already after a 2-h incubation (Fig. 4). Filaments with
diameters of 15–20 nm and lengths of several m long were
observed in both ERK2 or rat brain extract-phosphorylated
Tau-aggregated samples. The fibers showed the typical helical
appearance reported for PHF (49, 50). (Fig. 4, A and C). The
aggregation is specific for the phosphorylated Tau samples as
only rare isolated oligomers can be found in the control Tau
sample incubated at 35 °C (Fig. 4E). However, the aggregated
phosphoprotein only corresponded to a small fraction of the
incubated samples and was, therefore, not positive for thiofla-
vin detection, a fluorophore that detects amyloid fibril forma-
tion.We conclude that ERK2 by itself can generate a phosphor-
ylated protein whose aggregation properties resemble those of
the rat brain-phosphorylated protein. However, under our
experimental conditions a robust aggregation of the rat brain
extract-generated phospho-Tau was not observed.
Identification of the ERK2 Docking Site(s) on the Tau
Protein—MAP kinases recognize their substrates not only by
the phosphorylation (S/T)P motifs but also by docking motifs.
We thus next investigated the mechanism of Tau recognition
by ERK2. To map potential docking sites, two-dimensional
spectra of [15N]Tau mixed with recombinant ERK2 were com-
paredwith a reference spectrum from the [15N]Tau protein free
in solution (Fig. 5,A andD). The resonances in these spectra are
sensitive to their chemical environment and the local protein
dynamics, an interaction affecting their chemical shifts and/or
intensities. At a 1:5 [15N]Tau:ERK2 molar ratio, an interaction
indeed translates into an important broadening for numerous
resonances compared with the reference spectrum (Fig. 5, A
and D). Assignment of the Tau protein resonances has been
previously completed by us and others (51, 52) and was used to
map the interaction region(s) based on the two-dimensional
spectra perturbations. Peak intensities were compared for 187
resonances corresponding to residues dispersed along the 441-
amino acid residue Tau sequence (Fig. 5F). The data showed
interaction of ERK2 localizedmainly in theMTBDofTau (Tau-
(244–372); also called K18; Ref. 1). To increase the resolution,
the interaction experiment was repeated with Tau fragments,
Tau-(165–245), corresponding to the PRD, and Tau-(244–
372), corresponding to the MTBD (Figs. 5 and 6). The addition
of ERK2 to [15N]Tau-(165–245) resulted in minor perturba-
tions of the resonances in the corresponding two-dimensional
spectrum (Fig. 5B), whereas an interaction of ERK2 with Tau-
(244–372) is clearly observed as the intensity of several reso-
nances in its spectrum is affected (Figs. 5,C and E, and 6A). The
intensity of the resonances corresponding to amino acids
included in Tau-(274–288) and Tau-(306–318) segments
strongly decreased in the presence of ERK2 (Fig. 6A, I/I0
40%). These ERK2 docking sequences also correspond to,
respectively, the PHF6* (275VQIINK280) and PHF6 (306VQI-
VYK311) peptides described as nuclei of Tau aggregation (53).
Only the sequence of Tau-(274–288) can accommodate a
canonical D-site 274KVQIINKKLDL284 (Fig. 6B). Resonance
intensities of residues in the Tau-(346–358) segment also
showed a decrease upon ERK2 interaction but to a lesser extent
(Fig. 6A, I/I0 below 60%). This region could correspond to a
secondary binding site of interaction, although it is not clear if it
fits a classical ERK2 docking site.
Because the PHF sequences, respectively, located in R2 and
R3 repeated regions of the MTBD share similarities, it is likely
that these peptides would have the same binding mode to
ERK2. Yet only the PHF6* peptide can be matched to a D-site
FIGURE 3. Site-specific time course of in vitro Tau phosphorylation by
activated ERK2. A, 10% SDS-PAGE analysis of Tau incubated with activated
ERK2 for increasing time periods. B, rate constant T0 in minutes and correla-
tions. C, buildup of resonance integrals corresponding to Tau-phosphorylat-
ed residues, expressed as the fraction of maximum value reached during the
3-h reaction timeframe. Each data point is an average of three experiments
from two independent samples. S.D. is indicated by bars at each time point.
Data are fitted with a mono-exponential function 1-(e(t/T0)) with time t and
rate constant T0 in minutes (B). Correlation was calculated between the fit
and theaverageexperimental data.D, detail of 1H,15NHSQC two-dimensional
spectrum of Tau incubated with activated ERK2 for 60 min. The enlarged
region corresponds to the boxed region in Fig. 1, C and D. Resonances corre-
sponding to assigned phosphorylated Tau residues are annotated.
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sequence. To verify whether Tau interaction with ERK2 indeed
involves a canonical D-site, a mutated ERK2 was used in our
NMR binding assay. Replacement of two aspartic residues
(D321N/D324N) in the D-site peptide binding pocket of ERK2
by asparagine residues disrupts the recognition of the positively
charge residue  of the D-site docking peptide. The mutated
D321N/D324N ERK2 has consequently a reduced affinity for
the D-site peptides (28). However, we did not observe major
differences in the NMR intensity profiles of [15N]Tau-(244–
372) in presence of ERK2 or D321N/D324N-mutated ERK2
(Fig. 6A), indicating no major impact of the mutations on the
interaction.
Apparent KD values were calculated to further characterize
the Tau/ERK2 interaction using fluor NMR spectroscopy (54)
to confirm that the main binding is located in the MTBD (Fig.
7). The Tau protein and Tau-(244–372) (MTBD) were labeled
with fluor attached on the native Cys residues Cys-291 and
Cys-322 along the sequence (Fig. 6B). Chemical shift value per-
turbation of the fluor signal along titration of the ERK2 protein
on the labeled Tau or Tau fragment showed a saturation behav-
ior typical of an interaction (Fig. 7). The similar apparent KD
values of 73 M for Tau and 179 M for Tau-(244–372) frag-
ment indicated that the main binding indeed occurs within the
Tau-(244–372) segment. The data demonstrate that the main
binding sites of Tau for ERK2 are localized in theMTBDofTau,
in the Tau-(244–372) segment, outside of the regions contain-
ing ERK2 phosphorylation sites. The interaction is not medi-
ated by a classical D-site interaction and shows a moderate
FIGURE4.Self-assemblyof in vitrophosphorylatedTau.Representativeelectronmicrographsof thepelletsof variousTau samples at 5M incubatedat 35 °C
for 2 h. A and B, phospho-Tau, modified by activated ERK2. C and D, phospho-Tau, modified by rat brain extract kinase activity. E, unphosphorylated Tau
(incubated in phosphorylation mix without ATP), large field view. The scale bars in the lower right corners correspond to 500 nm.
FIGURE 5. ERK interactswith theMTBDof Tau.A–C, overlaid two-dimensional spectra corresponding to free Tau (black) and Tauwith a 5molar excess of ERK
(superimposed in red) (A), free Tau-(165–245) or PRD (black) and Tau-(165–245) with 1 mol eq of ERK2 (superimposed in green) (B), and free Tau-(244–372) or
MTBD (black) and Tau-(244–372) with 1 molar excess of ERK2 (superimposed in blue) (C). Boxed regions in A and C are enlarged and annotated in D and E. F,
relative intensities I/I0 of corresponding resonances in the two-dimensional spectra of Tauwith 5molar excess of ERK (I, red in A) or free in solution (I0, black in
A) for residues along the Tau sequence.
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affinity similar to the interaction of ERK2 by aminimal docking
sequence reported for some of its protein partners (55).
Tau Peptides Interaction with ERK2 Kinase—Two peptides
were next chosen to confirmwhether they interact individually
or not with the ERK2 docking site. The first peptide derived
from the Tau sequence, Tau-(220–240) in the PRD, contains
several ERK2 phosphorylation sites but no interaction site for
ERK2. On the other hand, Tau-(271–294) contains the Tau-
(274–284) sequence here above defined as an ERK2 docking
site. As the Tau-(271–294) peptide showed a limited solubility
(PHF6*), fusionswith the SUMOproteinwere used both for the
recombinant expression and two-dimensional spectra acquisi-
tion. SUMO being a small folded protein, the overlap with the
Tau peptide signals was limited and, therefore, allowed a cor-
rect analysis of Tau resonances (Fig. 8). Overlay of the two-
dimensional 1H,15N HSQC of the fusion peptides alone or
mixed with ERK2 confirms that the resonance perturbations
affected only those resonances corresponding to Tau peptides
and not to SUMO fusion protein (Fig. 8). Resonances corre-
sponding to Tau residues in SUMO-Tau-(220–240) are only
slightly affected by the addition of ERK2 (Fig. 8,A andC). To the
contrary, the addition of the kinase to the SUMO-Tau-(271–
294) affected peak intensities of most of the resonances and
principally residues 274 to 284 (Fig. 8, B and D). The peptides
Tau-(220–240) and Tau-(271–294) behaved in their interac-
tionwith ERK2 in the samemanner embedded in the protein or
isolated from their context. The data confirmed the sequence
Lys-274 to Leu-284 as a docking site of ERK2. Despite the pres-
ence in the Tau-(220–240) of a predicted D docking site con-
sensus sequence (Fig. 6B), no binding to ERK2 was observed.
FIGURE 6. ERK2 main interaction sites. A, relative intensities I/I0 of corre-
sponding resonances in the two-dimensional spectraof Tau-(244–372)witha
1 molar excess of ERK2 (I, blue diamonds) or D321N/D324N ERK2 (I, violet
diamonds), versus free in solution (I0). Double arrows indicate the interaction
regions along the sequence: Tau-(274–288), Tau-(306–318), and Tau-(346–
358). B, sequence of Tau. Perturbations of resonance intensities are color-
coded as red for residues with a I/I00.5 and orange0.6. Residues with no
information for the corresponding resonance are in gray. Tau-(244–372) or
MTBD is indicatedbyblue arrows along the sequence, andTau-(220–240) and
Tau-(271–294) peptides (Fig. 8) are indicated by red and black arrows, respec-
tively. The PHF6* and PHF6 peptides in the R2 and R3 repeats, respectively,
are boxed.
FIGURE 7. Determination of KD of Tau/ERK interaction. Shown are super-
imposed one-dimensional Fluor NMR spectra of CF3-Tau-(244–372) (A) and
CF3-Tau (B). C, saturation curves based on the chemical shift perturbation of
the Fluor signal of CF3-Tau and CF3-Tau-(244–372). The signal of only one
CF3-Cyswasmonitored along the titration, the secondonebeingbroadened.
FIGURE 8. Interaction of Tau peptideswith ERK2. A and B, detail of overlaid
1H,15N HSQC two-dimensional spectra of 15N-His-SUMO Tau-(220–240) (A)
and 15N-His-SUMOTau-(271–294) (B) free in solution (in black) orwith 1molar
excess of ERK2 (superimposed in red). Relative intensities ratio I/I0 for corre-
sponding resonances in these spectra are shown in C and D, respectively.
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Discussion
Using NMR spectroscopy, we identified Tau phosphoryla-
tion sites modified in vitro by the activated ERK2 and rat brain
extracts. We demonstrate that Tau phosphorylation patterns
observed with in vitro phosphorylation by ERK2 and rat brain
extracts are similar, withmost of the 17 (S/T)Pmotifsmodified.
Incorporation of 14–16 phosphates on (S/T)P sites per Tau
molecule was reported by the MAPK activity purified from the
brain extract (19). Our previous analysis of Tau phosphoryla-
tion patterns obtained in vitro by several other kinases showed
that none has the capacity to modify such a large number of
phosphorylation sites (43, 46, 47, 56). Phosphorylation by brain
extracts is a method to obtain in vitro phosphorylated Tau (12,
38) with AD-like characteristics (48) such as a reduced electro-
phoretic mobility on SDS-PAGE and positive immunodetec-
tion of the AT8 epitope (12, 38) and the Ser(P)-396/Ser(P)-404
epitope (57). Our work shows that ERK2 by itself also has the
potential to modify Tau into a phosphorylation state resem-
bling Tau present in pathological AD state.
Early work by Iqbal and co-workers (48) showed that a Tau
protein purified fromADbrain or hyperphosphorylated in vitro
by rat brain extract on 12–15 sites can form PHF-like aggre-
gates. We observed fibers with a morphology typical of the hel-
ical pattern described for the PHF in both the activated ERK2
and rat brain extract-phosphorylated Tau samples incubated at
35 °C for 2 h. Tau phosphorylated solely by ERK2 on 15 phos-
phorylation sites, dispersed along the Tau sequence, behaved
similarly as the rat brain extract-phosphorylated Tau in the
aggregation assays. This aggregation propensity is specific to
the phosphorylated Tau sample as we did not detect any PHF-
like structures in the control Tau samples. However, the
amount of fibers observed in our samples is small and could
only be detected by electron microscopy performed on the pel-
let of our aggregation samples. Compared with the aggregation
induced by the addition of heparin (58), the aggregation of the
in vitro phosphorylated Tau affects only a small fraction of the
sample. In agreementwith this observation, aTauproteinphos-
phorylated on 10 or 20 phosphorylation sites in insect sf9
cells was recently reported to form oligomers and only a small
fraction of fibrils (59). That the in vitro aggregation propensity
under near physiological conditions of the in vitro phosphory-
lated Tau is low does not exclude that it could be a trigger in a
cellular context, in which the aggregation process takes place
on a long time scale (60). Nevertheless, there are only a few
studies here above discussed that have explored the relation-
shipbetweenphosphorylationandaggregation.Thatphosphor-
ylation is a causative event of Tau aggregation should be stated
with more caution in regard of the data presented here by us
and recently by others (59).
Our analytical characterization of Tau phosphorylation
showed that ERK2 is promiscuous, as most of Tau (S/T)P
motifs were phosphorylated. The question of howMAPkinases
recognize specific substrates is only partially answered. We
investigated the interaction of ERK2 with Tau and identified
that it ismediated by twomain docking sites. To our knowledge
Tau is the first example of ERK2 protein substrate to contain a
combination of docking sites. A similar combination of three
D-docking sites was described in the regulatory disordered
N-terminal region ofMKK7 (MAP kinase kinase 7) used for the
specific recognition by the JNK MAP kinase (61, 62). Another
type of a modular system of recognition was previously pro-
posed consisting of a combination of the D-docking site and
F-docking site, although in this case it corresponds to two dis-
tinct binding grooves of ERK2 (34). Two binding sites on the
substrates for one recognition groove of ERK2 allows the for-
mation of a dynamic complex (63), defined as involving more
than two transient interfaces between the binding partners.
The presence of a high number of interaction sites on a flexible
ligand such as Tau, termed allovalency, increases the probabil-
ity of the rebinding of the protein partner (64, 65).
Comparison of the Tau interacting peptides with the degen-
erate ERK2 recognition sequence 1–3X3–7X (with  for
Arg/Lys residues, X for any residue, and  for hydrophobic
residues, the indices corresponding to the number of residues
(29, 30) shows that only the first peptide Tau-(274–284) corre-
sponds to predicted classical D-docking (Fig. 6B). We addition-
ally showed that a mutated ERK2 with two Asp residues
replaced byAsn residues in its docking pocket (D321N/D324N)
to compromise interaction with the residue in the D-peptide
(28) still binds Tau-(244–372) in the same manner as the wild
type ERK2 (Fig. 6A). Some docking interactions of ERK2 have
been reported to be limited to the hydrophobic pocket in the
D-peptide binding site (31).This is the case of the PEA-15 pro-
tein, as seen in the crystal structure of PEA15-ERK2 complex.
The structure also reveals a C-to-N reverse binding compared
with the classical D-peptide interaction. This type of docking
interaction is also characterized by a weaker affinity, with a
dissociation constant of 18 M reported for the PEA15/ERK2
interaction (31). This value is closer to the 10 M range that we
here found for the Tau/ERK2 interaction than the submicro-
molar range values reported for the canonical docking interac-
tion of ERK2 with D-site peptides (30, 55). It was proposed that
theminimal interactionmediated by the hydrophobic pocket of
ERK2 is a hallmark of moderate affinity regulatory interactions
(31). We showed that the Tau-(165–245) fragment does not
contain a docking site for ERK2. Nevertheless, phosphorylation
of Tau-(165–245) by activated ERK2 showed a similar pattern
and level of phosphorylation as with the full-length Tau sub-
strate (Fig. 2). This suggests that the enzymatic activity is not
affected by the docking and that the phosphorylation of the
PRDmight not require the ERK2 docking in theMTBD, at least
in the equilibrium conditions of our experiments. The essenti-
ality of docking sites for ERK2 to exert its efficient kinase activ-
ity is not established (29, 66, 67). Kinetic studies demonstrate
that docking sites that interact with either the D-recruitment
site or the F-recruitment site have little effect on the intrinsic
catalytic activity of ERK2 (66). In a proteomic study, a D-dock-
ing peptide was found only on 17% of the substrates within 20
amino acids of the phospho site (67). However, a peptide-based
study shows to the contrary, that a docking site is necessary to
mimic a ERK2 substrate (29). It might be in the case of Tau that
the docking sites are crucial to manage formation of regulatory
complexes in a cellular context rather than to stimulate activity
toward the protein partners (31).
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Activation of ERK1/2 is increased in AD neurons (68), is
found in associationwith abnormally phosphorylated early Tau
deposits (69), and is linked to the progression of the neurofibril-
lary degeneration through the Braak stages of AD (35, 60). Acti-
vation of ERK1/2 also responds to fibrillar amyloid deposits in
mature hippocampal neuronal culture (70) and to increased
activity of inositol-trisphosphate 3-kinase B (37) and oxidative
stress(71),allaffectingTauphosphorylation.ERK1/2phosphor-
ylation of Tau could thus take place in cells upon stress signal-
ing or once the phosphorylation fails to be counteracted by an
efficient dephosphorylation. ERK is thus accordingly consid-
ered as a Tau kinase that could be involved in AD pathophysi-
ology. We have reinforced this view by showing that ERK2 has
the capacity by itself to phosphorylate Tau onmany sites. These
results support the hypothesis that ERK activation under stress
conditionsmight have a detrimental effect for Tau function and
participate in AD physiopathology.
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